Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions

Journal of Clinical Oncology

Volumn 25, Issue 17, 2007, Pages 2420-2425

  D'Amico, Anthony V ^a   Denham, James W ^b   Crook, Juanita ^b   Chen, Ming Hui ^b   Goldhaber, Samuel Z ^b   Lamb, David S ^b   Joseph, David ^b   Tai, Keen Hun ^b   Malone, Shawn ^b   Ludgate, Charles ^b   Steigler, Allison ^b   Kantoff, Philip W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GOSERELIN; LEUPRORELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; WEIGHT GAIN;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 34347271955     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3369     Document Type: Article

References (31)

1. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7:165-170, 1988
2. Agency for Health Care and Research: Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. http://www.ahrq.gov/clinic/epcsums/prossumm.htm
3. Denham J, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
4. Hanks GE, Pajak TF, Porter A, et al: Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-3978, 2003
5. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
6. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression therapy and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-108, 2002
7. Park S, Meng MV, Elkin EP, et al: Androgen deprivation use with external beam radiation for prostate cancer: Results from CaPSURE. J Urol 174:1802-1807, 2005
8. Shahinian VB, Kuo YF, Freeman JL, et al: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer 103:1615-1624, 2005
9. Holzbeierlein JM, Castle E, Thrasher JB: Complications of androgen deprivation therapy: Prevention and treatment. Oncology 18:303-309, 2004
10. Malone S, Perry G, Segal R, et al: Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: Results of a phase II study. BJU Int 96:514-520, 2005
11. Smith JC, Bennett S, Evans LM, et al: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267, 2001
12. Hougaku H, Fleg JL, Najjar SS, et al: Relationship between androgenic hormones and arterial stiffness, based no longitudinal hormone measurements. Am J Physiol Endocrinol Metab 290:E234-E242, 2006
13. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006
14. Crook J, Ludgate C, Malone S, et al: Report of a multi-center Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60:15-23, 2004
15. Cleeman JI, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
16. Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
17. Wirth MP, See WA, McLeod DG, et al: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 172:1865-1870, 2004
18. Health Canada: Accelerated deaths using Casodex 150 mg in patients with localized prostate cancer. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb- dgpsa/pdf/medeff/casodex_hpc-cps_e.pdf
19. Grundy SM, Pasternak R, Greenland P, et al: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 34:1348-1359, 1999
20. Greene FL: Prostate, in Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 309-316
21. Agresti A: An Introduction to Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2002, pp 16-52
22. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
23. Gaynor JJ, Feur EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
24. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
25. Oefelein MG: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration. J Urol 160: 1685-1688, 1996
26. D'Amico AV, Renshaw AA, Loffredo B, et al: Duration of androgen suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormonal therapy. Presented at the 3rd Annual American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, FL, February, 22-24, 2007
27. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
28. Neter J, Wassermann W, Kutner M (eds): Simultaneous inferences and other topics in regression analyses-1, in Applied Linear Regression Models. Homewood, IL, McGraw-Hill, 1983, pp 150-153
29. Beyer DC, McKeough T, Thomas T: Impact of short course hormonal therapy on overall and cancer-specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61:1299-1305, 2005
30. Norata GD, Tibolla G, Seccomandi PM, et al: Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91:546-554, 2006
31. Beller GA, Zaret BL: Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 101:1465-1478, 2000